
|Videos|November 23, 2021
Dr. Bander on PSMA breakthroughs in prostate cancer
Author(s)Urology Times staff
“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.
Advertisement
In this video, Neil H. Bander, MD, discusses PSMA therapeutic innovations for patients with prostate cancer and how they will change diagnosis and treatment. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The Expert APProach: Focal Therapy and Precision Prostate Cancer Care, With Anup A. Vora, MD
2
Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH
3
Urocross shows sustained benefit through 24 months post-removal
4
Updated AUA/SUO Advanced Prostate Cancer guideline emphasizes role of PSMA-PET
5












